nach oben

Die Urologie

Erschienen in:

01.04.2008 | Leitthema

HIFU in der Uro-Onkologie

verfasst von: S. Thüroff, Prof. Dr. C. Chaussy

Erschienen in: Die Urologie | Ausgabe 4/2008

Einloggen, um Zugang zu erhalten

Zusammenfassung

Das Interesse an der Technologie des „hochintensiven fokussierten Ultraschalls“ (HIFU) ist vor allem auf dessen nichtinvasiven Therapiecharakter zurückzuführen. In der urologischen Onkologie findet HIFU als therapeutische Maßnahme zur Behandlung des Prostata- und Nierenkarzinoms Anwendung. Während die Therapie des Nierenkarzinoms noch in experimentellen und klinischen Studien geprüft wird, ist die Therapie mit HIFU in vielen Zentren Europas und darüber hinaus als Therapie des Prostatakarzinoms bereits etabliert. Die Ergebnisse der Therapie des Prostatakarzinoms mit HIFU beruhen in der Hauptsache auf Patientenserien unterschiedlicher klinischer Studien. In den USA wurde vor ca. 1/2 Jahr eine prospektive Multicenterstudie im Vergleich zur Cryotherapie zur Erreichung der klinischen Zulassung (FDA approval) begonnen. Die neuesten Publikationen sehen in der transrektalen HIFU-Therapie eine erfolgversprechende Option bei hoch- und mitteldifferenzierten Tumoren, bei lokalen Rezidiven erfolgloser anderer Primärtherapien und als unterstützende auxiliäre palliative Therapiemöglichkeit des systemischen Prostatakarzinoms.

Adams JB, Moore RG, Anderson JH et al. (1996) High-intensity focused ultrasound ablation of rabbit kidney tumors. J Endourol 10: 71–75PubMedCrossRef

Beerlage HP, van Leenders GJ, Oosterhof GO, et al. (1999) High-intensity focused ultrasound (HIFU) followed after one to two weeks by radical retropubic prostatectomy: results of a prospective study. Prostate 39: 41–46PubMedCrossRef

Blana A, Murat FJ, Walter B, et al. (2007) First Analysis of the Long-Term Results with Transrectal HIFU in Patients with Localised Prostate Cancer. Eur Urol [Epub ahead of print]

Blana A, Walter B, Rogenhofer S, Wieland WF(2004) High-intensity focused ultrasound for the treatment of localized prostate cancer: 5-year experience. Urology 64: 297–300CrossRef

Chapelon JY, Margonari J, Vernier F et al. (1992) In vivo effects of high-intensity ultrasound on prostatic adenocarcinoma Dunning R3327. Cancer Res 52: 6353–6357PubMed

Chapelon JY et al. (2000). Med Biol 26: 153–159

Chaussy C, Thüroff S (2000) High-intensive focused ultrasound in localized prostate cancer. J Endourol 14: 293–299PubMedCrossRef

Chaussy C, Thüroff S (2003) The status of high-intensity focused ultrasound in the treatment of localized prostate cancer and the impact of a combined resection. Curr Urol Rep 4: 248–252PubMedCrossRef

Chaussy C, Thüroff S, Rebillard X, Gelet A (2005) Technology insight: High-intensity focused ultrasound for urologic cancers. Nat Clin Pract Urol 2(4): 191–198PubMedCrossRef

10.

Chaussy C, Thüroff S, Bergsdorf T (2006) Local recurrence of prostate cancer after curative therapy. HIFU (Ablatherm) as a treatment option. Urologe A 45 (10): 1271–1275PubMedCrossRef

11.

Chapelon JY, Margonari J, Theillère Y et al. (1992) Effects of high-energy focused ultrasound on kidney tissue in the rat and the dog. Eur Urol 22: 147–152PubMed

12.

Chavrier F, Chapelon JY, Gelet A, Cathignol D et al. (2000) Modeling of high-intensity focused ultrasound-induced lesions in the presence of cavitation bubbles. J Acoust Soc Am 108: 432–440PubMedCrossRef

13.

Ciezki, Klein EA, Angermeier K et al. (2004) A retrospective comparison of androgen deprivation (AD) vs. no AD among low-risk and intermediate-risk prostate cancer patients treated with brachytherapy, external beam radiotherapy, or radical prostatectomy. Int J Radiat Oncol Biol Phys 60: 1347–1350PubMed

14.

Curiel L, Chavrier F, Souchon R, Birer A, Chapelon JY (2002) 1.5-D high intensity focused ultrasound array for non-invasive prostate cancer surgery. IEEE Trans Ultrason Ferroelectr Freq Control 49: 231–242PubMedCrossRef

15.

Curiel L, Chavrier F, Gignoux B et al. (2004) Experimental evaluation of lesion prediction modelling in the presence of cavitation bubbles: intended for high-intensity focused ultrasound prostate treatment. Med Biol Eng Comput 42: 44–54PubMedCrossRef

16.

Damianou CA et al. (1995). IEEE 42: 182–187

17.

Damianou C (2003) In vitro and in vivo ablation of porcine renal tissues using high-intensity focused ultrasound. Ultrasound Med Biol 29: 1321–1330PubMedCrossRef

18.

Damianou C, Pavlou M, Velev O, Kyriakou K, Trimikliniotis M (2004).High intensity focused ultrasound ablation of kidney guided by MRI. Ultrasound Med Biol 30: 397–404PubMedCrossRef

19.

Ficarra, Antoniolli SZ, Novara G et al. (2006) Short-term outcome after high-intensity focused ultrasound in the treatment of patients with high-risk prostate cancer. BJU Int 98: 1193–1198PubMedCrossRef

20.

Foster RS, Bihrle R, Sanghvi N et al. (1993) Production of prostatic lesions in canines using transrectally administered high-intensity focused ultrasound. Eur Urol 23: 330–336PubMed

21.

Fry FJ, Johnson LK (1978)Tumor irradiation with intense ultrasound. Ultrasound Med Biol 4: 337–341PubMedCrossRef

22.

Gelet A, Chapelon JY, Margonari J et al. (1993) Prostatic tissue destruction by high-intensity focused ultrasound: experimentation on canine prostate. J Endourol 7: 249–253PubMedCrossRef

23.

Gelet A, Chapelon JY, Bouvier R et al. (2000) Transrectal high-intensity focused ultrasound: minimally invasive therapy of localized prostate cancer. J Endourol 14(6): 519–528PubMedCrossRef

24.

Gelet A, Chapelon JY, Bouvier R et al. (2001) Transrectal high intensity focused ultrasound for the treatment of localized prostate cancer: factors influencing the outcome. Eur Urol 40(2): 124–129PubMedCrossRef

25.

Gelet A, Chapelon JY, Poissonnier L et al. (2004) Local recurrence of prostate cancer after external beam radiotherapy: early experience of salvage therapy using high-intensity focused ultrasonography. Urology 63: 625–629PubMedCrossRef

26.

Goldner, Wachter S, Wachter-Gerstner N, Dieckmann K, Pötter R et al. (2006) Long-term results in three-dimensional conformal radiotherapy of localized prostate cancer at moderate dose (66 Gy). Strahlenther Onkol 182: 537–542PubMedCrossRef

27.

Haar G ter (2000). Med Biol 23 (Suppl 1): S51–S54

28.

Hynynen K, Freund WR, Cline HE (1996) A clinical, noninvasive, MR imaging-monitored ultrasound surgery method. Radiographics 16: 185–195PubMed

29.

Kishi M et al. (1975) Proceedings of the 2nd European Congress on Ultrasonics in Medicine: 28–33 (eds. Kazmer E et al.) Excerpta Medica, Amsterdam

30.

Köhrmann KU, Michel MS, Gaa J, Marlinghaus E, Alken P et al. (2002) High intensity focused ultrasound as noninvasive therapy for multilocal renal cell carcinoma: case study and review of the literature. J Urol 167: 2397–2403PubMedCrossRef

31.

Köhrmann KU, Michel MS, Steidler A et al. (2002) Technical characterization of an ultrasound source for noninvasive thermoablation by high-intensity focused ultrasound. BJU Int 90: 248–252PubMedCrossRef

32.

Lu J et al. (1996). IEEE 2: 1299–1302

33.

Lynn JG, Putman TJ (1944). Am J Pathol 20: 637–649

34.

De Meerleer GO Fonteyne VH, Vakaet L et al. (2007) Intensity-modulated radiation therapy for prostate cancer: late morbidity and results on biochemical control. Radiother Oncol 82: 160–166CrossRef

35.

Moore WE, Lopez RM, Matthews DE et al. (1989) Evaluation of high-intensity therapeutic ultrasound irradiation in the treatment of experimental hepatoma. J Pediatr Surg 24: 30–33PubMedCrossRef

36.

Oosterhof GO, Cornel EB, Smits GA, Debruyne FM, Schalken JA (1997) Influence of high-intensity focused ultrasound on the development of metastases. Eur Urol 32: 91–95 PubMed

37.

Poissonnier L, Gelet A, Chapelon JY et al. (2003) Results of transrectal focused ultrasound for the treatment of localized prostate cancer (120 patients with PSA < or + 10 ng/ml). Prog Urol 13: 60–72PubMed

38.

Poissonnier, Chapelon JY, Rouvière O (2007) Control of prostate cancer by transrectal HIFU in 227 patients. Eur Urol 51: 381–387PubMedCrossRef

39.

Lee HM, Hong JH, Choi HY (2006) High-intensity focused ultrasound therapy for clinically localized prostate cancer. Prostate Cancer Prostatic Dis 9(4): 439-443PubMedCrossRef

40.

Rébillard X Davin JL, Soulié M et al. (2003) Treatment by HIFU of prostate cancer: survey of literature and treatment indications. Prog Urol 13: 1428–1456PubMed

41.

Rouvière O, Lyonnet D, Raudrant A et al. (2001) MRI appearance of prostate following transrectal HIFU ablation of localized cancer. Eur Urol 40: 265–274PubMedCrossRef

42.

Sanghvi NT et al. (2003). Ultrasound Med Biol 29: S102

43.

Sedelaar JP, Aarnink RG, van Leenders GJ et al. (2000) The application of three-dimensional contrast-enhanced ultrasound to measure volume of affected tissue after HIFU treatment for localized prostate cancer. Eur Urol 37: 559–568PubMedCrossRef

44.

Souchon R, Rouvière O, Gelet A et al. (2003) Visualisation of HIFU lesions using elastography of the human prostate in vivo: preliminary results. Ultrasound Med Biol 29: 1007–1015PubMedCrossRef

45.

Stokes SH (2000) Comparison of biochemical disease-free survival of patients with localized carcinoma of the prostate undergoing radical prostatectomy, transperineal ultrasound-guided radioactive seed implantation, or definitive external beam irradiation. Int J Radiat Oncol Biol Phys 47: 129–136PubMed

46.

Tan JS et al. (2000). IEEE 2: 1247–1251

47.

Thüroff S, Chaussy C (2000) High-intensity focused ultrasound: complications and adverse events. Mol Urol 4: 183–187PubMed

48.

Thüroff S, Chaussy C, Vallancien G et al. (2003) High-intensity focused ultrasound and localized prostate cancer: efficacy results from the European multicentric study. J Endourol 17: 673–677PubMedCrossRef

49.

Uchida T et al. (2002). Urology 59: 394–398PubMedCrossRef

50.

Uchida, Baba S, Irie A et al. (2005) Transrectal high-intensity focused ultrasound in the treatment of localized prostate cancer: a multicenter study. Hinyokika Kiyo 51: 651–658PubMed

51.

Uchida, Ohkusa H, Yamashita H et al. (2006) Five years experience of transrectal high-intensity focused ultrasound using the Sonablate device in the treatment of localized prostate cancer. Int J Urol 13: 228–233PubMedCrossRef

52.

Uchida, Illing RO, Cathcart PJ, Emberton M et al. (2006) The effect of neoadjuvant androgen suppression on prostate cancer-related outcomes after high-intensity focused ultrasound therapy. BJU Int 98: 770–772PubMedCrossRef

53.

Vaezy S, Shi X, Martin RW et al. (2001) Real-time visualization of high-intensity focused ultrasound treatment using ultrasound imaging. Ultrasound Med Biol 27: 33–42PubMedCrossRef

54.

Vallancien G, Chartier-Kastler E, Chopin D et al. (1991) Focussed extracorporeal pyrotherapy: experimental results. Eur Urol 20: 211–219PubMed

55.

Vallancien G, Chartier-Kastler E, Harouni M, Chopin D, Bougaran J et al. (1993) Focused extracorporeal pyrotherapy: experimental study and feasibility in man. Semin Urol 11: 7–9PubMed

56.

Vallancien G, Prapotnich D, Cathelineau X, Baumert H, Rozet F et al. (2004) Transrectal focused ultrasound combined with transurethral resection of the prostate for the treatment of localized prostate cancer: feasibility study. J Urol 171: 2265–2267PubMedCrossRef

57.

Watkin NA, Morris SB, Rivens IH, ter Haar GR et al. (1997) High-intensity focused ultrasound ablation of the kidney in a large animal model. J Endourol 11: 191–196PubMedCrossRef

58.

Wu T, Felmlee JP, Greenleaf JF, Riederer SJ, Ehman RL et al. (2001) Assessment of thermal tissue ablation with MR elastography. Magn Reson Med 45: 80–87PubMedCrossRef

59.

Wu F, Wang ZB, Chen WZ et al. (2003) Preliminary experience using high intensity focused ultrasound for the treatment of patients with advanced stage renal malignancy. J Urol 170: 2237–2240PubMedCrossRef

60.

Yang R, Reilly CR, Rescorla FJ et al. (1991) High-intensity focused ultrasound in the treatment of experimental liver cancer. Arch Surg 126: 1002–1009PubMed

Titel: HIFU in der Uro-Onkologie
verfasst von: S. Thüroff
Prof. Dr. C. Chaussy
Publikationsdatum: 01.04.2008
Verlag: Springer-Verlag
Erschienen in: Die Urologie / Ausgabe 4/2008
Print ISSN: 2731-7064
Elektronische ISSN: 2731-7072
DOI: https://doi.org/10.1007/s00120-008-1658-9

Neu im Fachgebiet Urologie

24.04.2024 | DGIM 2024 | Nachrichten

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

HIFU in der Uro-Onkologie

Zusammenfassung

Neu im Fachgebiet Urologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Stufenschema weist Prostatakarzinom zuverlässig nach

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Varikozelen bei Jugendlichen: Das Für und Wider der Operation

Update Urologie

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2008

Die Kryoablation des Prostatakarzinoms

Von der Nephrektomie über Lebendspende bis zur Nierenteilresektion

15. Jahrestagung des Arbeitskreises Nierentransplantation der Akademie der Deutschen Urologen

Penoskrotale Elephantiasis

Roboterassistierte laparoskopische Prostatektomie

Berufspolitik BDU

Neu im Fachgebiet Urologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Stufenschema weist Prostatakarzinom zuverlässig nach

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Varikozelen bei Jugendlichen: Das Für und Wider der Operation

Update Urologie